Scinovex
article Open AccessTop 1% cited

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

Immunity · 2007 · Vol. 27(1) · pp. 111–122
Manish J. ButteMary KeirTheresa B. PhamduyArlene H. SharpeGordon J. Freeman
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune ResponsesBiologyCell biologyProgrammed cell deathLigand (biochemistry)CellReceptorApoptosisBiochemistry

MeSH terms

AnimalsCell LineCells, CulturedChlorocebus aethiopsHumansLigandsMembrane GlycoproteinsMice, Inbred C57BLPeptidesProtein BindingT-LymphocytesDown-RegulationCytokinesB7-1 AntigenMice, Knockout

Funding

  • GlaxoSmithKline
  • Beth Israel Deaconess Medical Center
  • Harvard University
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases
  • National Center for Research Resources
Citations
1,731
FWCI
22.81
field-weighted impact
References
56
Percentile
100%
vs. same field & year
Citations per year
Cited by
PD-1 and Its Ligands in Tolerance and Immunity
Annual Review of Immunology · 2008 · 5,272 citations
Role of the PD-1 Pathway in the Immune Response
American Journal of Transplantation · 2012 · 427 citations
Immune Checkpoint Blockade in Cancer Therapy
Journal of Clinical Oncology · 2015 · 2,706 citations
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Journal of Cellular Physiology · 2018 · 506 citations
PD‐1 signaling in primary T cells
Immunological Reviews · 2009 · 762 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.